Background: Naftifine hydrochloride 1% gel (NAFT-1) is a FDA-approved topical product containing a synthetic, broad-spectrum antifungal agent and is indicated for the topical treatment of tinea pedis, tinea cruris, and tinea corporis. Seborrheic dermatitis is a chronic inflammatory disorder affecting areas of the head and trunk where sebaceous glands are prominent. Although fairly common, the etiology is not clear. However, a causal relationship is implied because of the ability to isolate Malassezia furfur or ovalis in patients with seborrheic dermatitis and by its therapeutic response to antifungal agents. Objective: To assess the efficacy and safety of NAFT-1 in the treatment of seborrheic dermatitis of the scalp.